NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

Lung Cancer Clinical Trial

Official title:

A Multicenter Study of the NEUWAVE Flex Microwave Ablation System in the Ablation of Medically Inoperable Primary Soft Tissue Lesions of the Lung: An Initial Experience

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03603652
• Other study ID #: NEU_2017_06
• Status: Terminated
• Phase: N/A
• Start date: June 29, 2018
• Est. completion date: October 24, 2019

Study information

• Verified date: December 2020
• Source: Ethicon, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with medically inoperable primary soft tissue lesion of the lung will have transbronchial microwave ablation performed via transbronchial approach by an interventional pulmonologist or thoracic surgeon using CT imaging. Prior to the ablation procedure, the treating physician will use endobronchial ultrasound to confirm staging. Patients will be followed for one year following the ablation procedure for efficacy and safety.

Description:

Patients with medically inoperable primary soft tissue lesion of the lung (lesions less than or equal to 2cm and located in the outer two-thirds of the lung and not closer than 1cm to the pleura) will have transbronchial microwave ablation performed using CT imaging. All ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.

Prior to the ablation procedure, the treating physician will use endobronchial ultrasound to confirm staging.

Patients will be followed for one year following the ablation procedure for efficacy and safety with specific follow-up visits at 30 days, 6 months, and 12 months post-ablation. A user experience questionnaire is completed by the treating physician to better understand the ease of the procedure.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: October 24, 2019
• Est. primary completion date: December 21, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent.

2. Patients = 18 years old.

3. Performance status 0-2 via ECOG (Eastern Cooperative Oncology Group) classification.

4. Willing to fulfill all follow-up visit requirements.

5. Medically inoperable primary soft tissue lesion of the lung or patient election not to have surgery. (Medically inoperable is defined per the following indicators: post op predictive FEV1 (forced expiratory volume in 1 second) < 40%; DLCO (diffusing capacity of the lung for carbon monoxide) < 40%; hypoxemia or hypercapnia diabetes with end-organ damage; or severe cerebral, cardiovascular, peripheral vascular disease, or chronic heart disease)

6. One soft tissue lesion = 2 cm in the outer two thirds of the lung and not closer than 1 cm to the pleura.

(Outer two thirds of the lung is defined as peripheral beyond the segmental airway, past the segmental bronchi, such that proximal endobronchial soft tissue lesions are avoided; soft tissue lesions should not be contiguous with the pleura)

7. Radiographic resolution of pneumonia

Exclusion Criteria:

1. Scheduled concurrent procedure for the target soft tissue lesion other than those that are lung related.

2. Pregnant or breastfeeding.

3. Physical or psychological condition that would impair study participation.

4. Patients with uncorrectable coagulography at time of screening.

5. Patient with implantable devices, including pacemakers or other electronic implants.

6. Prior pneumonectomy or bronchiectasis.

7. Severe neuromuscular disease.

8. Platelet count = 50,000/mm3.

9. ASA (American Society of Anesthesiologists) score of = 4.

10. Inability to tolerate anesthesia.

11. Expected survival less than 6 months.

12. Clinically significant hypertension.

13. Chronic ventilator support, which uses bi-level positive airway pressure (PAP).

14. Endobronchial soft tissue lesions proximal to the segmental airways

Related Conditions & MeSH terms

• Cancer of Lung
• Cancer of the Lung
• Carcinoma
• Carcinoma, Non-Small Cell Lung
• Carcinoma, Non-Small-Cell Lung
• Lung Cancer
• Lung Neoplasms
• Neoplasms, Lung
• Non-Small Cell Lung Cancer
• Non-Small-Cell Lung Carcinoma

Intervention

Device:
• Microwave Ablation
Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound to confirm disease staging.

Locations

Country	Name	City	State
United States	Cleveland Clinic	Cleveland	Ohio
United States	City of Hope	Duarte	California
United States	New York Presbyterian-Weill Cornell Medicine	New York	New York
United States	FirstHealth Moore Regional Hospital	Pinehurst	North Carolina
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Ethicon, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients Whose Ablation Resulted in Technical Success	Ablation of the target lesion according to the protocol and covered completely, with an adequate margin, as defined by the performing physician (that is, the ablation zone completely overlaps or encompasses the target lesion plus an ablative margin), as assessed by CBCT imaging, immediately following the procedure.	Immediately post-ablation (day 0)
Primary	Number of Patients Whose Ablation Resulted in Technique Efficacy	Ablation of the target lesion according to the protocol and covered completely, with an adequate margin, as defined by the performing physician (that is, the ablation zone completely overlaps or encompasses the target lesion plus an ablative margin), as assessed by CT imaging, 30 days (+/- 7 days) after the first ablation procedure.	30 days post-ablation
Primary	User Experience Survey (Part I)	A Sponsor-created survey completed by the treating physician immediately post-ablation. Questions were all YES/NO.	Immediately post-ablation
Primary	User Experience Survey (Part II)	A Sponsor-created survey completed by the treating physician immediately post-ablation. This question asked the time it took to place the probe in a position that was ready for ablation.	Immediately post-ablation
Primary	User Experience Survey (Part III)	A Sponsor-created survey completed by the treating physician immediately post-ablation. This question asked how many cone-beam CT (CBCT) scans were taken to place the probe such that it was ready for ablation.	Immediately post-ablation
Primary	User Experience Survey (Part IV)	A Sponsor-created survey completed by the treating physician immediately post-ablation. This question asked the distance of the tip of the probe to the center of the soft-tissue lesion (in mm) just before the ablation procedure was initiated.	Immediately post-ablation
Primary	User Experience Survey (Part V)	A Sponsor-created survey completed by the treating physician immediately post-ablation. This question asked how many times the probe had to be repositioned to complete the ablation procedure.	Immediately post-ablation
Secondary	Number of Patients Who Experienced Target Lesion Recurrence	Analyzed at 6 months and 1 year post-ablation via CT imaging	measured at 6 months and 1 year post-ablation
Secondary	Number of Patients Who Were Readmitted to the Hospital	Any readmission to the hospital within 30 days of the ablation procedure.	Within 30 days post-ablation